Open AccessEsophageal Cancer: New Insights into a Heterogenous Disease
Author(s) -
Sebastian Krug,
Patrick Michl
Publication year - 2017
Publication title -
digestion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.882
H-Index - 75
eISSN - 1421-9867
pISSN - 0012-2823
DOI - 10.1159/000464130
Subject(s) - medicine , neoadjuvant therapy , esophageal cancer , oncology , perioperative , malignancy , tolerability , cancer , chemoradiotherapy , chemotherapy , clinical trial , multimodal therapy , surgery , adverse effect , breast cancer
Esophageal cancer represents a heterogeneous malignancy mostly diagnosed in advanced stages. Worldwide, squamous cell carcinomas (SCCs) continue to be the most prevalent subtype; however, in the Western countries, the incidence of adenocarcinomas is increasing and will exceed that of SCC in the near future. During the last decade, several landmark trials contributed to a better understanding of the disease and emphasized the importance of multimodal treatment protocols.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom